Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
Cabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion. While it is a well-described complication of dopamine agonist therapy in Parkinson’s disease, only three convincing cases of CA...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-01-01
|
| Series: | Endocrine Oncology |
| Subjects: | |
| Online Access: | https://eo.bioscientifica.com/view/journals/eo/3/1/EO-22-0086.xml |
| _version_ | 1811177285454135296 |
|---|---|
| author | Annabelle G Hayes Masoumeh G Shirazi Anand Thiyagarajah David J Torpy Sunita M C De Sousa |
| author_facet | Annabelle G Hayes Masoumeh G Shirazi Anand Thiyagarajah David J Torpy Sunita M C De Sousa |
| author_sort | Annabelle G Hayes |
| collection | DOAJ |
| description | Cabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion. While it is a well-described complication of dopamine agonist therapy in Parkinson’s disease, only three convincing cases of CAV have previously been described in the treatment of prolactinoma, with none involving the tricuspid valve. We describe a case of CAV affecting the tricuspid valve, ultimately resulting in the patient’s death. The novel finding of CAV affecting the tricuspid valve suggests a possible link between confirmed cases of CAV and the echocardiographic surveillance studies of cabergoline-treated prolactinoma patients which have mostly demonstrated subclinical tricuspid valve changes. The risk of CAV, although small, prompts a mindful prescription of dopamine agonist therapy for prolactinomas and consideration of measures to minimise cabergoline exposure. The cumulative cabergoline doses and duration of therapy associated with CAV in published cases exceed what has been evaluated in case series and surveillance studies, underscoring the importance of case reports in understanding CAV. |
| first_indexed | 2024-04-10T23:00:17Z |
| format | Article |
| id | doaj.art-863e7720e938410590198ce40bfb7872 |
| institution | Directory Open Access Journal |
| issn | 2634-4793 |
| language | English |
| last_indexed | 2024-04-10T23:00:17Z |
| publishDate | 2023-01-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Oncology |
| spelling | doaj.art-863e7720e938410590198ce40bfb78722023-01-14T02:18:23ZengBioscientificaEndocrine Oncology2634-47932023-01-013116https://doi.org/10.1530/EO-22-0086Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinomaAnnabelle G Hayes0Masoumeh G Shirazi1Anand Thiyagarajah2David J Torpy3Sunita M C De Sousa4Flinders Medical Centre, Adelaide, SA, Australia; University of Adelaide, Adelaide, SA, AustraliaUniversity of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, AustraliaUniversity of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, AustraliaUniversity of Adelaide, Adelaide, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, AustraliaUniversity of Adelaide, Adelaide, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA, AustraliaCabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion. While it is a well-described complication of dopamine agonist therapy in Parkinson’s disease, only three convincing cases of CAV have previously been described in the treatment of prolactinoma, with none involving the tricuspid valve. We describe a case of CAV affecting the tricuspid valve, ultimately resulting in the patient’s death. The novel finding of CAV affecting the tricuspid valve suggests a possible link between confirmed cases of CAV and the echocardiographic surveillance studies of cabergoline-treated prolactinoma patients which have mostly demonstrated subclinical tricuspid valve changes. The risk of CAV, although small, prompts a mindful prescription of dopamine agonist therapy for prolactinomas and consideration of measures to minimise cabergoline exposure. The cumulative cabergoline doses and duration of therapy associated with CAV in published cases exceed what has been evaluated in case series and surveillance studies, underscoring the importance of case reports in understanding CAV.https://eo.bioscientifica.com/view/journals/eo/3/1/EO-22-0086.xmlprolactinomadopamine agonistcabergolinevalvulopathytricuspidcabergoline-associated valvulopathy |
| spellingShingle | Annabelle G Hayes Masoumeh G Shirazi Anand Thiyagarajah David J Torpy Sunita M C De Sousa Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma Endocrine Oncology prolactinoma dopamine agonist cabergoline valvulopathy tricuspid cabergoline-associated valvulopathy |
| title | Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| title_full | Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| title_fullStr | Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| title_full_unstemmed | Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| title_short | Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| title_sort | cabergoline associated valvulopathy of the tricuspid valve in the treatment of prolactinoma |
| topic | prolactinoma dopamine agonist cabergoline valvulopathy tricuspid cabergoline-associated valvulopathy |
| url | https://eo.bioscientifica.com/view/journals/eo/3/1/EO-22-0086.xml |
| work_keys_str_mv | AT annabelleghayes cabergolineassociatedvalvulopathyofthetricuspidvalveinthetreatmentofprolactinoma AT masoumehgshirazi cabergolineassociatedvalvulopathyofthetricuspidvalveinthetreatmentofprolactinoma AT anandthiyagarajah cabergolineassociatedvalvulopathyofthetricuspidvalveinthetreatmentofprolactinoma AT davidjtorpy cabergolineassociatedvalvulopathyofthetricuspidvalveinthetreatmentofprolactinoma AT sunitamcdesousa cabergolineassociatedvalvulopathyofthetricuspidvalveinthetreatmentofprolactinoma |